Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096720 · ClinicalTrials.gov registry record · Phase 2
Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease
A Phase 2 study, sponsored by Institute for Neurodegenerative Disorders.
- Completed
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
NCT00096720 is a Phase 2 study that has completed, run by Institute for Neurodegenerative Disorders. The registered enrollment target is 112 participants.
The verdict
NCT00096720, a Phase 2 study, has completed, sponsored by Institute for Neurodegenerative Disorders.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
Study Summary
Study participants who have been clinically diagnosed with Parkinson disease will receive no treatment, treatment with either levodopa, or treatment with Mirapex for a period of 12 weeks. Over the course of the study subjects will travel to the Institute for Neurodegenerative Disorders (IND) in New Haven, Connecticut for brain imaging.
Interventions
- DRUG levodopa
- DRUG Mirapex (pramipexole)
- PROCEDURE [123I]ß-CIT and SPECT imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2004-02 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00096720
The ClinicalTrials.gov registry entry for NCT00096720 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Institute for Neurodegenerative Disorders, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which levodopa is the first listed.
NCT00096720 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00096720 about?
NCT00096720 is a clinical study titled "Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease". Study participants who have been clinically diagnosed with Parkinson disease will receive no treatment, treatment with either levodopa, or treatment with Mirapex for a period of 12 weeks. Over the course of the study subjects will travel to the Institute for Neurodegenerative Disorders (IND) in New ...
What is the current status of trial NCT00096720?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2004-02. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00096720?
The interventions under investigation include: levodopa (DRUG), Mirapex (pramipexole) (DRUG), [123I]ß-CIT and SPECT imaging (PROCEDURE).
Who is sponsoring clinical trial NCT00096720?
This trial is sponsored by Institute for Neurodegenerative Disorders, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.